David Pariser, MD
Division of Dermatology, Eastern Virginia Medical School, Norfolk, Va.
Carol Opper
Clinical Research Scientist, Novartis Pharmaceuticals Corporation, East Hanover, N.J.

David Pariser, MD

Division of Dermatology, Eastern Virginia Medical School, Norfolk, Va.

Carol Opper

Clinical Research Scientist, Novartis Pharmaceuticals Corporation, East Hanover, N.J.


Purpose: To evaluate in-office dermatophyte test medium (DTM) culture as an alternative to traditional laboratory fungal culture for confirming a diagnosis of onychomycosis, and to determine the prevalence of dermatophytes as a cause of onychomycosis in patients not participating in a clinical trial.

Design: This nationwide multicenter prospective study enrolled 1100 adult patients with suspect onychomycosis. DTM and laboratory fungal culture results were compared for individual patients.

Methodology: The 310 participating physicians obtained patient nail-bed specimens and divided them for testing by both diagnostic methods. The paired results of the two culture methods were compared using the kappa statistic.

Principal findings: Paired culture results were available for 975 of the 1100 enrolled patients. DTM results agreed with central laboratory cultures in 70 percent of cases. The kappa value of 0.40 indicated a moderate degree of correspondence between the two testing modalities. Overall, DTM culture indicated a dermatophyte in 616 patient specimens (56 percent) and central laboratory culture identified a dermatophyte in 528 of the specimens (48 percent). For the entire study population, dermatophytes were identified in 93 percent of the positive central laboratory cultures, confirming that dermatophytes caused the vast majority of the infections. The cost of each DTM culture was approximately $1, compared to $25 for each laboratory fungal culture.

Conclusion: This study demonstrates that the in-office DTM culture for diagnosing onychomycosis has comparable utility to the traditional laboratory fungal culture, is less expensive, and yields faster results.

Key terms: onychomycosis, dermatophytes, dermatophyte test medium, DTM, fungal infection, mycology.

Author correspondence:
David Pariser, MD
Pariser Dermatology Specialists
601 Medical Tower
Norfolk, VA 23507
Phone: (757) 622-6315
Fax: (757) 625-6940
E-mail: dpariser@pariserderm.com

This study was funded through a grant provided by Novartis Pharmaceuticals Corporation.

This paper has undergone peer review by appropriate members of Managed Care's Editorial Advisory Board.

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.